Target (TGT) Stock Is Up, What You Need To Know

Target shares rose about 3.4% to close at $134.12 after Wolfe Research upgraded TGT to Outperform from Peer Perform, named it a Top Pick into year-end, and set a $162 price target (~25% upside). Wolfe cited improving store performance and positive customer trends, raising 2026 EPS to $8.48 and 2027 to $9.52. Target also announced a multi-season Hollister partnership.

Original reporting
Published Jun 23, 2026, 9:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 23, 2026, 9:27 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Target (TGT) Stock Is Up, What You Need To Know — source image
Decision brief

The 30-second read

$TGTBullishMed
01

Why it matters

For traders, the actionable element is the same-day upgrade with a Street-high $162 target and raised 2026/2027 EPS estimates, which can shift near-term positioning and relative performance.

02

Market read

TGT rallied on a fresh sell-side catalyst (upgrade + target + EPS raises) and additional product/partnership news, with the broader tape also supported by easing oil/inflation fears.

03

What to watch

The article’s macro discussion is about Iran/Fed expectations, which can dominate near-term tape; TGT’s follow-through may depend more on rates/oil than on the analyst note.

Relevance 8/10Novelty 7/10Timing: same-day afternoon upgrade/price-target catalyst

Background

Wolfe Research upgraded Target to Outperform, citing improving store execution and positive customer trends, and anchored the call on Q1 results reported May 20.

Company-level read

Ticker impact

$TGTBullishMedium confidence
Context

Target shares jumped ~3.5% after Wolfe Research upgraded to Outperform, named a Top Pick, and set a $162 price target with EPS raises.

Expected impact

Likely supports continued relative strength versus retailers over the next days/weeks, though magnitude may fade if no new fundamental datapoints follow.

Evidence & confidence

The article cites a same-session upgrade with explicit EPS revisions and a high target; that combination typically drives incremental demand, but no new company operational disclosure beyond Q1 comps is added.

Market effects

Read-through favors value/consumer-discretionary retailers as money rotates away from expensive AI names, potentially improving relative flows to large-box retail.

US retail sentiment bid alongside broader risk-on moves tied to reduced oil/inflation pressure.

Limited direct global linkage; macro backdrop (oil/Fed expectations) can influence discretionary demand and discount rates.

Counterpoint

The move may be largely sell-side-driven; without new company guidance beyond already-reported Q1 data, upside could mean-revert after the initial upgrade effect.

Key entities

  • Target

    General merchandise retailer; upgraded to Outperform with a $162 price target and higher EPS estimates.

  • Wolfe Research

    Issued the upgrade, Top Pick designation, and Street-high target that drove the stock’s intraday jump.

  • Hollister (Abercrombie & Fitch brand)

    Partnered with Target for a multi-season collaboration including apparel and home/décor items.

Related articles

$AMZNMed

NYC Mayor Zohran Mamdani Sends Cease-and-Desist Letters to Amazon, Target Over E-Bikes

NYC Mayor Zohran Mamdani sent cease-and-desist letters to about 40 retailers, including Amazon, Target, Walmart, Wayfair and Temu, demanding they stop selling motorized scooters and e-bikes he says violate city law. The letters cite speed and wattage limits and require VINs. Noncompliance could bring fines up to $2,000 per sale, starting Aug. 18. Amazon said it is reviewing products.

$PGMed

Drugmakers, retailers must face ’maximum strength’ claim in decongestant false ad litigation in US

Nasdaq sees best day in over a month as Microsoft breathes life back into AI trade By Jonathan Stempel NEW YORK, July 30 (Reuters) - A federal appeals court on Thursday revived portions of nationwide litigation in which consumers accused drugmakers such as Procter & Gamble and retailers such as CVS of selling billions of dollars of over-the-counter decongestants that didn’t work. The litigation comprised about 100 lawsuits filed after a U.S.